AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
(nesiritide, Scios Inc.)
A recombinant form of human B-type natriuretic peptide (hBNP) for people with acutely decompensated congestive heart failure (CHF), with shortness of breath at rest or with minimal activity. This is the first new treatment approved for decompensated CHF in more than a decade.
Dosage: A loading IV bolus dose of 2 [micro]g/kg, followed by a continuous infusion at a dose of 0.01 [micro]g/kg.
Special Considerations: In the pivotal trial, the rate of symptomatic hypotension in the first 24 hours was similar with IV nitroglycerin (5% of patients) and Natrecor (4%). The episodes lasted significantly longer in those on Natrecor, which has a relatively long half-life and should be administered in a setting where blood pressure can be closely monitored.
Comment: This form of hBNP produced by the left ...
Source: HighBeam Research, Natrecor. (New & Approved: Natrecor * InSync Cardiac...